Chadi Nabhan, MD, MBA, FACP
Chadhi Nabhan, MD, MBA, FACP, is a hematologist/oncologist and award-winning host of the “Outspoken Oncology” and “Healthcare Unfiltered” podcasts.
Articles by Chadi Nabhan, MD, MBA, FACP
HMAs such as decitabine and cedazuridine (Inqovi) have become the “cornerstone” of treating high-risk patients.
"Having something that could cure patients after failing CAR-T is huge,” host Dr. Chadi Nabhan said during the episode.
It's many different diseases, and it falls across many different specialties, according to the Dr. Goodman.
Dr. Chadi Nabhan brings "The HemOnc Pulse" live to Chicago May 3-4.
Elias Jabbour, MD, joined "The HemOnc Pulse" to discuss the function of MRD in treating ALL.
Drs. Dahiya and Spiegel return for the second half of a discussion on reports of secondary T-cell malignancies after CAR-T.
In episode four of the 2024 season, Dr. Coombs shares updates in CHIP from ASH 2023.
Drs. Saurabh Dahiya and Jay Spiegel stop by The HemOnc Pulse to discuss the recent news on CAR-T therapies and the FDA.
The latest HemOnc Pulse episode looks at the science behind the statement from the FDA on the risk of CAR-T therapies.
This episode of The HemOnc Pulse features Dr. Shastri, a physician-scientist, who discusses latest news in MDS.
Susan Parsons, MD, MRP; Andrew Evans, DO, MBA, MSc; and Matthew Maurer, DMSc; discuss the HoLISTIC consortium.
Dr. Usmani shares insights on the evolution in myeloma treatment since he first started practicing.
Dr. Venugopal offers her thoughts on the investigational drug KER-050 in lower-risk myelodysplastic syndromes.
"MRD positivity is an indication to go to transplant in these patients,” Dr. Radich said.
Dr. Woyach joined Chadi Nabhan, MD, MBA, FACP, to discuss the novel BTK inhibitors pirtobrutinib and LP168.
Drs. Lonial, Nabhan, and Stewart discussed the plenary session at ASH, the PERSEUS trial, and treating smoldering MM.
In this episode of The HemOnc Pulse, Alan Skarbnik, MD, of Novant Health, discusses practice-changing research in DLBCL.
The debate on the future of Bruton's tyrosine kinase (BTK) inhibitors in CLL.
Drs. Nabhan, Coombs, and Danilov discussed the BRUIN, TRANSCEND, and FLAIR trials in CLL.
The SEER database was used to examine disparities in incidence and survival outcomes between different races.
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC. All rights reserved.